WallStSmart

Basel Medical Group Ltd Ordinary Shares (BMGL)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 172756% more annual revenue ($19.63B vs $11.35M). FMS leads profitability with a 5.0% profit margin vs -93.7%. FMS earns a higher WallStSmart Score of 62/100 (C+).

BMGL

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -1.69

FMS

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 5.0Value: 10.0Quality: 7.0
Piotroski: 6/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BMGL.

FMSUndervalued (+73.4%)

Margin of Safety

+73.4%

Fair Value

$90.32

Current Price

$22.26

$68.06 discount

UndervaluedFair: $90.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMGL2 strengths · Avg: 8.0/10
Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
27.3%8/10

Revenue surging 27.3% year-over-year

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

Areas to Watch

BMGL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$13.95M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-1.6%2/10

ROE of -1.6% — below average capital efficiency

FMS4 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.2%4/10

4.2% earnings growth

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BMGL

The strongest argument for BMGL centers on Price/Book, Revenue Growth. Revenue growth of 27.3% demonstrates continued momentum.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bear Case : BMGL

The primary concerns for BMGL are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : FMS

The primary concerns for FMS are EPS Growth, Altman Z-Score, Return on Equity. Thin 5.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

BMGL profiles as a growth stock while FMS is a value play — different risk/reward profiles.

BMGL is growing revenue faster at 27.3% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (62/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Basel Medical Group Ltd Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.

Visit Website →

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?